$6.7MSeed, 22 September 2025
Milestone-based investment from Marathon to take its radiotheranostics toward first-in-human trials.
- Amount
- $6.7M
- Stage
- Seed
- Announced
- 22 September 2025
- Lead
- Marathon Beteiligungs AG
- Use of funds
- Milestone-based investment from Marathon to take its radiotheranostics toward first-in-human trials.
- Checked
- Announced by the company
- Sources
- King's spin-out Nuclide Therapeutics secures £5 million investment - King's College London kcl.ac.uk
King's spin-out Nuclide Therapeutics secures £5 million investment - King's College London King's College London
King's spin-out Nuclide Therapeutics secures £5 million investment - King's College London funding.tech.eu